Groupe 1 Concomitant N = 99 (171 metastases) | % | Group 2 Non concomitant N = 95 (131 metastases) | % | Difference p-value | |
---|---|---|---|---|---|
Gender | 0.124 | ||||
Female | 49 | 49 | 36 | 38 | |
Male | 50 | 51 | 59 | 62 | |
KPS median (range) | 90 | (60–100) | 90 | (60–100) | 0.230 |
Age median (range) | 61 | (38–85) | 60 | (24–84) | 0.530 |
Primary | |||||
Lung | 60/99 | 60 | 70/95 | 75 | 0.004 |
EGFR+ | 18/60 | 30 | 1/70 | 1.5 | |
ALK+ | 7/60 | 12 | 3/70 | 4 | |
PDL1 > 1% | 26/60 | 43 | 1/70 | 1.5 | |
Breast | 19/99 | 19 | 9/95 | 9 | 0.177 |
HER2+++ | 13/19 | 68 | 1/9 | 11 | |
Melanoma | 13/99 | 13 | 4/95 | 4 | 0.049 |
GU | 2/99 | 2 | 4/95 | 4 | 0.987 |
GI | 5/99 | 5 | 8/95 | 8 | 0.461 |
Number of BMs (range) | 2 | (1–5) | 2 | (1–7) | 0.998 |
Tumor size (cm) | |||||
< 2 cm | 129/171 | 76 | 88/131 | 67 | 0.109 |
2-3 cm | 28/171 | 16 | 32/131 | 25 | 0.072 |
> 3 cm | 14/171 | 8 | 11/131 | 8 | 0.831 |
Prior WBRT | |||||
Yes | 25 | 25 | 24 | 26 | 0.995 |
No | 74 | 74 | 71 | 74 | |
DS GPA (range) | 2,5 | (0.5–3.5) | 2,5 | (0.5–3.5) | 0.999 |
RPA | |||||
I | 18/99 | 18 | 45/95 | 47 | < 0.001 |
II | 78/99 | 79 | 47/95 | 50 | < 0.001 |
III | 3/99 | 3 | 3/95 | 3 | 0.673 |
ECM | |||||
Yes | 56 | 56 | 32 | 34 | 0.002 |
No | 43 | 43 | 63 | 66 | |
Treatments | |||||
CT | 33/99 | 33 | 64/95 | 67 | < 0.001 |
Before | 14/33 | 48/64 | |||
After | 23/33 | 19/64 | |||
IT | 30/99 | 30 | 6/95 | 6 | < 0.001 |
Before | 15/30 | 4/6 | |||
After | 16/30 | 2/6 | |||
TT | 36/99 | 36 | 17/95 | 18 | 0.031 |
Before | 22/36 | 9/17 | |||
After | 27/33 | 8/17 | |||
HT | 4/99 | 4 | 1/94 | 1 | 0.403 |
Dosimetric parameters | |||||
HG | 87/171 | 51 | 65/131 | 49 | 0.783 |
INH | 84/171 | 49 | 66/131 | 51 |